PharmEasy has cut costs sharply to turn Ebitda positive. It hopes this will help in the next fund-raising round. But it has come at the cost of growth. How long will this trade-off be sustainable?
Janus Henderson reduced the valuation of its holding in the firm by half which translates into an approximate valuation of $2.8 billion as of December 31, 2022.
ETtech Exclusive: PharmEasy gets $300 million booster shot for Thyrocare deal
SECTIONS
Last Updated: Jun 28, 2021, 08:08 AM IST
Share
Synopsis
PharmEasy has raised $300 million more, bringing the total funding received by the online pharmacy since April to $650 million, most of which will be used to fund its ongoing acquisition of diagnostics chain Thyrocare.
ETtech
The Pharmeasy-Thyrocare deal will allow the online pharmacy to offer four key elements of healthcare information, consult, test and treatment at a time when online adoption is growing due to the pandemic. (Illustration: Rahul Awasthi/ETtech)
Bengaluru:PharmEasy has raised $300 million more, led by its existing investors, bringing the total funding received by the online pharmacy since April to $650 million, most of which will be used to fund its ongoing acquisition of diagnostic chain Thyrocare, a top executive told ET.